Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Drug Store News3d
Generic drug suppliers weigh in on predictable, unpredictable category impact
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
pharmaphorum3d
When licensing deals go bad - Novo sues KBP Bio for $830m
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Semaglutide Side Effects: Is It Safe? What You Need To Know
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...